Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why This Stock Has Missed the Mark in 2013

The markets have delivered in a big way for investors in 2013, but not every stock out there has satisfied its investors. Even among big pharma stocks --many of which have posted superb years so far -- a few big names haven't lived up to the market's run. Take French pharmaceutical giant Sanofi (NYSE: SNY  ) : This stock boasts a diverse drug portfolio and the top blockbuster diabetes therapy Lantus, which made $5 billion last year. Still, that hasn't been enough to save Sanofi's stock from a lackluster year, as shares only have posted low single-digit percentage growth in 2013.

Sanofi's facing challenges endemic to big pharma companies, particularly in regards to the patent cliff. While Sanofi has managed to ride Lantus higher in making its name as one of the most dominant firms in treating diabetes, can this top drug get this stock back on track?

This is one stock health care investors need to watch with a close eye over the near future. In the video below, Fool contributor Dan Carroll explains what has hurt Sanofi's stock in 2013 and the hurdles that this company will have to clear to get shares back on track.

Sanofi's sluggish stock hasn't impressed investors this year, but you don't have to settle for a low-growth portfolio. Time to spruce up your portfolio: Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 13, 2013, at 2:14 PM, GameBot wrote:

    I don't see the point of this story.

    SNY delivers a good div, has had a good price move over the last two years. Plus it is an EU based company providing some exposure....

    I consider this a stock worth holding.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2636527, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:52:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:03 PM
SNY $38.67 Up +0.52 +1.36%
Sanofi CAPS Rating: *****
^GSPC $2171.37 Up +11.44 +0.53%
S&P 500 INDEX CAPS Rating: No stars
BIIB $310.55 Down -3.98 -1.27%
Biogen CAPS Rating: *****
NVO $43.74 Down -0.11 -0.25%
Novo Nordisk CAPS Rating: *****